Oxcarbazepine

REFERENCES

• TECOMA ES: Oxcarbazepine. Epilepsia (1999) 40\(Suppl. 5):537–546.
   Google Scholar
• MCLEAN MJ, SCHMUTZ M, WAMIL AW et al.: Oxcarbazepine: mechanisms of action. Epilepsia (1994) 35\(Suppl. 3):55–59.
   Google Scholar
• WAMIL AW, SCHMUTZ M, PORTET C etal.: Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur. Pharmacal. (1994) 271(2–3):301–308.
   Google Scholar
• CALABRESI P, DE MURTAS M, STEFANI A et al.: Action of GP 47779, the active metabolite of oxcarbazepine on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia (1995) 36(10):990–996.
   Google Scholar
• STEFANI A, PISANI A, DE MURTAS M etal.: Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia (1995) 36(10):997–1002.
   Google Scholar
• GRUNER WAND SILVA LR: to-Conotoxin sensitivity and presynaptic inhibition of glutamergic sensory neurotransmission in vitro. j Neurosci. (1994) 14:2800–2808.
   Google Scholar
• JENSEN PK, GRAM L, SCHMUTZ M: Oxcarbazepine. Epilepsy Res. (1991) 3:135–140.
   Google Scholar
• KUBOVA H AND MARES P: Anticonvulsant action of oxcarbazepine, hydrocarbamazepine, and carbamazepine against metrazol-induced motor seizures in developing rats. Epilepsia (1993) 34(1):188–192.
   Google Scholar
• GRANT SM, FAULDS D: Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia, and affective disorders. Dugs (1992) 43:873–888.
   Google Scholar
• LLOYD P, FLESCH G, DIETERLE W: Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia (1994) 35\(Suppl. 3):S10–S13.
   Google Scholar
• PERUCCA E: The clinical pharmaco-kinetics of the new antiepileptic drugs. Epilepsia (1999) 40\(Suppl. 9):S7–S13.
   Google Scholar
• SCHUTZ H, FELDMAN KF, FAIGLE JW et al.: The metabolism of MC-oxcarbazepine in man. Xenabiatica (1986) 16:769–78.
   PubMed Web of Science ®Google Scholar
• JUNG H, NOGUEZ A, MAYET L et al.: The distribution of 10-hydroxycarbazepine in blood compartments. Biapharm. Drug Disposit. (1997) 18:17–23.
   Google Scholar
• GONZALEZ-ESQUIVEL DE ORTEGA-GAVILAN M, ALCANTARA-LOPEZ Get al.: Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med. Res. (2000) 31(2):202–205.
   Google Scholar
• BARUZZI A, ALBANI F, RIVA R: Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia (1994) 35\(Suppl. 3):514–519.
   Google Scholar
• VAN DER KUY PH, KOPPEJAN EH, WIRTZ JJ: Rectal absorbtion of oxcarbazepine. Pharm. World Sci. (2000) 22 (4):165–166.
   Google Scholar
• LARKIN JG, MCKEE PJW, FORREST G et al.: Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br. J. Cliii. Pharmacal. (1991) 31:65–71.
   Google Scholar
• BULAU P, PAAR WD, VON UNRUH GE: Pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine in the new-born child of an oxcarbazepine-treated mother. Eur.Pharmacal. (1988) 34(3):311–313.
   Google Scholar
• PIENIMAKI E LAMPELA E, HAKKOLA J: Pharmacokinetics of oxcarbazepine in human placenta. Epilepsia (1997) 38(3):309–316.
   Google Scholar
• ROUAN MC, LECAILLON JB, GODBILLON J et al.: The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur. Pharmacal. (1994) 47(2):161–167.
   Google Scholar
• SALLAS W, HOSSAIN M, D'SOUZA J: Population pharmacokinetic analysis of oxcarbazepine (Trileptal9 in children with epilepsy. Epilepsia (1999) 40\(Suppl. 7):S102.
   Google Scholar
• KERANEN T, JOLKKONEN J, JENSEN PK et al.: Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neural. Land. (1992a) 85(4):239–242.
   Google Scholar
• KERANEN T, JOLKKONEN J, JENSEN PK et al.: Absence of interaction between oxcarbazepine and erythromycin. Acta Neural. Land. (1992b) 86(2):120–123.
   PubMed Web of Science ®Google Scholar
• KRAMER G, TETTENBORN B, KLOSTERKOV-JENSEN P et al.: Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia (1992) 33:1145–1148.
   Google Scholar
• ZACCARA G, GANGEMI PF, BENDONI L et al.: Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther. Drug Monitor. (1993) 15:39–42.
   PubMed Web of Science ®Google Scholar
• FATTORE C, CIPOLLA G, GATTI G et al.: Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia (1999) 40(6):783–787.
   PubMed Web of Science ®Google Scholar
• SONNEN AEH: Oxcarbazepine and oral contraceptives. Acta Neural. Scalar/. (1990) 82\(Suppl. 1):33–37.
   Google Scholar
• JENSEN PK, SAANO V, HARING P et al.: Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia (1992) 33:1149–52.
   PubMed Web of Science ®Google Scholar
• ISOJARVI JI, PAKARAINEN AJ, RAUTIO A et al.: Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur. j Cliii. Pharmacal. (1995) 47:461–464.
   PubMed Web of Science ®Google Scholar
• RATTYA J, VAINIONPA I, KNIP Metal.: The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics (1999) 103:588–93.
   Google Scholar
• TANAKA E: Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. j. Cliii. Pharm. Ther. (1999) 24:87–92.
   Google Scholar
• SCHMIDT D AND SACHDEO R: Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav. (2000) 1:396–405.
   Google Scholar
• BARCS G, WALKER EB, ELGER CE et al.: Oxcarbazepine: placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia (2000) 42 (12) :1597–1607.
   Google Scholar
• GLAUSER TA, NIGRO M, SACHDEO RC et al.: Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology (2000) 54:2237–2244.
   PubMed Web of Science ®Google Scholar
• SCHACHTER SC, VAZQUEZ B, FISHER RS et al.: Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology (1999) 52:732–737.
   PubMed Web of Science ®Google Scholar
• BEYDOUN A, SACHDEO RC, ROSENFELD WE et al.: Oxcarbazepine monotherapy for partial-onset seizures: a multicentre, double-blind, clinical trial. Neurology (2000) 54:2245–2251.
   PubMed Web of Science ®Google Scholar
• SACHDEO R, BEYDOUN A, SCHACHTER SC et al.: Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology (2001) 57(5):864–871.
   PubMed Web of Science ®Google Scholar
• SACHDEO R, EDWARDS K, HASEGAWA H et al.: Safety and efficacy of oxcarbazepine 1200 mg/day in patients with recent-onset partial epilepsy. Neurology (1999) 52\(Suppl. 2):A391. Abstract.
   Google Scholar
• BILL PA, VIGONIUS U, POHLMANN H et al: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. (1997) 27:195–204.
   PubMed Web of Science ®Google Scholar
• GUERREIRO MM, VIGONIUS U, POHLMANN H et al.: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. (1997) 27:205–213.
   PubMed Web of Science ®Google Scholar
• CHRISTE W, KRAMER G, VIGONIUS U et al: A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. (1997) 26:451–460.
   PubMed Web of Science ®Google Scholar
• DAM M, EKBERG R, LOYNING Y, WALTIMO 0, JAKOBSEN K: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. (1989) 3:70–76.
   PubMed Web of Science ®Google Scholar
• DAM M: Practical aspects of oxcarbazepinetreatment. Epilepsia (1994) 35\(Suppl. 3):S23–S25.
   Google Scholar
• EMRICH HM, ALTMANN H, DOSE M et al.: Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report. Pharmacal Biochem. Behav. (1983) 19:369–372.
   PubMed Web of Science ®Google Scholar
• SPINA E, PISANI F, PERUCCA E: Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. OM. Pharmacalcin. (1996) 31:198–214.
   Google Scholar
• SHUKLA S, GOLDWIN CD, LONG LE et al.: Lithium-carbamazepine neurotoxicity and risk factors. Am. j Psychiatr. (1984) 141:1604–1606.
   PubMed Web of Science ®Google Scholar
• PISANI E OTERI G, RUSSO M et al.: Double-blind, within-patient study to evaluate the influence of viloxazine on the steady state plasma levels of oxcarbazepine and its metabolites. Epilepsia (1991) 32\(Suppl. 1):70.
   Google Scholar
• CAMPBELL FG, GRAHAM JG, ZILKHA KJ: Clinical trial of carbamazepine (Tegretol) in trigeminal neurolgia. j Neural Neurosurg. Psych. (1966) 29:265–267.
   PubMed Web of Science ®Google Scholar
• KILLIAN JM, FROMM GH: Carbamazepine in the treatment of neurolgia. Use and side effects. Arch. Neural (1968) 19:129–136.
   PubMed Web of Science ®Google Scholar
• NICOL CF: A four year double-blind study of tegretol in facial pain. Headache (1968) 9:54–57.
   Google Scholar
• REMILLARD G: Epilepsia (1994) 35\(Suppl. 3):528–529.
   Google Scholar
• FARAGO F: Trigeminal neuralgia: its treatment with two new carbamazepine analogues. Eur. Neural (1987) 26:73–83.
   PubMed Web of Science ®Google Scholar
• ZAKRZEWSKA JM, PATSALOS PN: Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. j Neural Neurosurg. Psych. (1989) 52:472–476.
   PubMed Web of Science ®Google Scholar
• LINDSTROM P: The analgesic effect of carbamazepine in trigeminal neuralgia. Path (1987) (Suppl 4):585.
   Google Scholar
• ROYAL M,WIENECKE G, MOVVA V et al.: Open-label trial of oxcarbazepine in neuropathic pain. 2nd World Congress of World Institute of Pain. Istanbul, Turkey (2001). Abstract.
   Google Scholar
• ROGIN JB: Oxcarbazepine in treatment of painful peripheral neuropathies. Epilepsy Behav. (2000) 1:454.
   Google Scholar
• DEVOR M: Neuropathic pain and injured nerve: peripheral mechanisms. Br Med. Bull. (1991) 47:630.
   Google Scholar
• BERAN RG: Cross reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia (1993) 34:163–165.
   PubMed Web of Science ®Google Scholar
• NIELSEN OA, JOHANNESSEN AC, BARDRUM B: Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy Res. (1988) 2(4):269–271.
   PubMed Web of Science ®Google Scholar
• PENDLEBURY SC, MOSES DK, EADIE MJ: Hyponatraemia during oxcarbazepine therapy. Hum. Taxical (1989) 8(5):337–344.
   PubMedGoogle Scholar
• ROSENDAHL L, FRIIS ML: Metabolic encephalopathy: oxcarbazepine (Trileptal)-induced hyponatraemia. Ugeskrift for Laeger (1991) 153(38):2637–2638.
   Google Scholar
• STEINHOFF BJ, STOLL KD, STODIECK SR et al: Hyponatremic coma under oxcarbazepine therapy. Epilepsy Res. (1992) 11(1):67–70.
   PubMed Web of Science ®Google Scholar
• REINIKAINEN KJ, KERANEN T, HALONEN T et al.: Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res. (1987) 1:284–289.
   PubMed Web of Science ®Google Scholar
• AIKIA M, KALVIAINEN R, SIVENIUS J et al: Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res. (1992) 11:199–203.
   PubMed Web of Science ®Google Scholar
• CURRAN HV, JAVA R: Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur. Pharmacy]. (1993) 44:529–533.
   Google Scholar
• ZACCARA G, GANGEMI PF, MESSORI A et al.: Effects of oxcarbazepine and carbamazepine on the central nervous system: computerised analysis of saccadic and smooth-pursuit eye movements. Acta Neural Land. (1992) 85(6):425–429.
   PubMed Web of Science ®Google Scholar
• DANNER R, PARTANEN J, KERANEN T et al.: Comparison of the effects of carbamazepine and oxcarbazepine on peripheral nerve conduction. Epilepsy Res. (1988) 2(4):272–275.
   Google Scholar